Insider buying last 90 days
No open-market insider purchases were filed for HAE in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every HAE insider filing, plotted on the chart in Gekko.Open HAE in Gekko
NYSE: HAE
Haemonetics (HAE) Stock Analysis & Forecast
Sep 28 close
$105.79+0.49 (+0.5%)
Gekko Brief
AI summaryHaemonetics has been highlighted this week as a top-ranked momentum stock, with commentary pointing to its recent stock performance, financial metrics and analyst ratings. Coverage also touched on volatility and options greeks, reflecting continued attention on trading activity around the name. These pieces follow Haemonetics' Q1 FY2027 results reported on 6 August, in which revenue reached $339 million, up 6% reported and organic year-over-year, adjusted EPS grew 4% to $1.14, and Interventional Technologies returned to growth at 3% organically.
Shares closed at $105.79, up 0.5%, sitting above both the 50-day average of $96.71 and the 200-day average of $74.60, with the shorter average above the longer one. The GekkoIndex reads 50.7, placing HAE in the Neutral zone. Price remains 15.7% below the Gekko Fair Value of $125.49.
The next earnings date falls on 5 November, 37 days out and beyond a typical 20-trading-day holding window; the prior report showed an average absolute reaction of 14.7% and eight EPS beats over eight quarters. Smart-money data show one trailblazer holder, with no insider, Congress or unusual options activity recorded in the respective windows. Seasonality over five years shows a 0.7% average 20-day return from this point, rising in 2 of those years. Consensus among 8 firms stands at 6 buy, 2 hold, with a target of $111.50.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Haemonetics price vs fair value
Close $105.79200-day averageGekko Fair Value $125.49
Haemonetics quick facts
- Market cap
- $4.81B
- P/E ratio
- 50.9
- Forward P/E
- 20.3
- EPS, TTM
- $2.07
- Revenue, TTM
- $1.35B
- Profit margin
- 7.1%
- Dividend yield
- —
- Beta
- 0.54
- Volume
- 472,147 avg 590,430
- 1-year return
- +121.9%
- Typical daily move
- ±2.5%
- Typical 20-day move
- ±6.8%
- 50-day average
- $96.71
- 200-day average
- $74.60
- Next earnings
- Nov 5 before open
- Shares outstanding
- 45.50M
Haemonetics swing-trade checklist
Haemonetics scores 3 supportive, 2 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed0 headwinds
- Trendsupportive
Above 50 and 200-day
Close $105.79 is above the 50-day ($96.71) and 200-day ($74.60) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
50.7, Neutral
Reading 50.7 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
15.7% below
Price is 15.7% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 37 days
Next report Nov 5, 2026, 37 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+0.7% on average
From this point in the calendar, the next 20 trading days averaged +0.7% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Haemonetics stock chart and price history
Haemonetics closed at $105.79 on Sep 28, 2026, +121.9% over the past year, inside a 52-week range of $47.32 to $110.45.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +0.8%
- 3 months
- +40.8%
- 6 months
- +95.8%
- 1 year
- +121.9%
The full HAE chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open HAE in Gekko
Follow Haemonetics through every session
Put HAE on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track HAE in GekkoFree for 7 days. No credit card required.
About Haemonetics
Haemonetics makes medical devices and software used in blood and plasma management. Its products range from automated plasma collection systems to blood component collection technology and hospital tools that measure how well a patient's blood clots, with the hemostasis analyzers and autologous blood recovery systems among its recognized offerings.
The business is organized around three areas: plasma, blood centers, and hospitals. In plasma, it supplies collection devices along with donor management and IT systems that help customers track donors and supply chains. Its blood center offerings include apheresis equipment for collecting blood components and software for managing blood bank operations and transfusions. On the hospital side, it provides clotting analysis systems paired with software that lets clinicians review test results across a facility, plus equipment for recovering a patient's own blood during surgery. Haemonetics reaches customers through its own sales staff as well as independent distributors and representatives.
The company was founded in 1971 and is headquartered in Boston, Massachusetts. Its shares are listed on the NYSE under the ticker HAE.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- haemonetics.com
Haemonetics GekkoIndex: the smart money zone
Haemonetics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 50.7, in the Neutral zone, up 5.9 points over five sessions.
50.7Neutral
Up 5.9 points over five sessions, from the Distribution zone.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 89 | −0.6% | +1.6% |
| Accumulation | 219 | −0.1% | +2.1% |
| Neutral (current zone) | 277 | +0.8% | +1.8% |
| Distribution | 76 | +1.6% | +2.3% |
| Selling | 11 | −0.3% | +1.4% |
Average HAE share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the HAE price, zone by zone.Track HAE in Gekko
Is Haemonetics stock overvalued? Gekko Fair Value
Haemonetics trades 15.7% below Gekko Fair Value of $125.49, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Haemonetics shares are worth, recalculated every trading day.
$125.49
Gekko Fair Value, Sep 29, 2026
15.7% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open HAE in Gekko
Haemonetics insider and Congress trading
No open-market insider purchases were filed for Haemonetics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in HAE were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for HAE, plotted on the chart in Gekko.Open HAE in Gekko
Buybacks
Haemonetics has been buying back its own shares.
- Bought back, quarter ended Jun 27, 2026
- $3.50M
- As a share of market cap
- 0.07%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds HAE.
0added0opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Haemonetics earnings: next date and track record
Haemonetics reports on Nov 5, 2026, before the open (37 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected before the open, 37 days away
- EPS estimate
- $1.30
- Revenue estimate
- $345.1M
8 of 8reports beat the EPS estimate
±14.7%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 6, 2026 AI summary
- What they said
- Haemonetics reported Q1 FY2027 revenue of $339 million, up 6% reported and organic year-over-year. Adjusted EPS grew 4% to $1.14. MedSurg revenue rose 6% to $148 million, with Blood Management Technologies growing 8% organically including mid-teens Hemostasis disposable growth. Interventional Technologies returned to growth at 3% organically, with Vascular Closure up low-double-digits. Company raised full fiscal 2027 guidance.
- Guidance
- Management raised fiscal 2027 guidance following strong Q1 results. Company expects mid-single-digit MedSurg growth for the full year, driven by Hemostasis, Transfusion Management, and recovering Vascular Closure momentum across geographies.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | $1.14 est $1.07 | — | +5.1% |
| May 7, 2026 | $1.29 est $1.27 | $346.4M est $336.8M | +4.7% |
| Feb 5, 2026 | $1.31 est $1.27 | $339.0M est $331.9M | −10.0% |
| Nov 6, 2025 | $1.27 est $1.12 | $327.3M est $329.8M | +34.8% |
| Aug 7, 2025 | $1.10 est $1.01 | $321.4M est $320.0M | −28.7% |
| May 8, 2025 | $1.24 est $1.22 | $330.6M est $312.5M | +6.1% |
| Feb 6, 2025 | $1.19 est $1.18 | $348.5M est $354.5M | −16.7% |
| Nov 7, 2024 | $1.12 est $1.09 | $345.5M est $342.7M | +11.8% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Haemonetics stock forecast and analyst price targets
Analysts’ average 12-month price target for Haemonetics is $111.50, +5.4% from the last close, from 8 firms rating the stock in the last 90 days.
$111.50consensus 12-month target, +5.4% from the last close
Now $105.79Avg $111.50
Low $86High $125
Each firm’s latest rating in the last 90 days: 8 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 17 | Citi | $123 | +16.3% |
| Sep 3 | Raymond James | $125 | +18.2% |
| Aug 21 | Robert W. Baird | $119 | +12.5% |
| Aug 19 | Barrington | $118 | +11.5% |
| Aug 18 | Needham | — | — |
+1.8%average 20-day move after past Neutral readings
+0.7%average move over the next 20 trading days in the last 5 years
±2.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Haemonetics seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Haemonetics averaged +0.7% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | 0.0% | 3 of 5 |
| Next 10 trading days | +0.6% | 2 of 5 |
| Next 15 trading days | +1.6% | 3 of 5 |
| Next 20 trading days | +0.7% | 2 of 5 |
| Next 30 trading days | +10.5% | 3 of 5 |
For scale, HAE’s typical 20-trading-day move in either direction is about 6.8%.
Haemonetics market cap and key statistics
Haemonetics’s market cap is $4.81B, with a P/E ratio of 50.9 and revenue of $1.35B over the last twelve months.
Valuation
- Market cap
- $4.81B
- P/E ratio
- 50.9
- Forward P/E
- 20.3
- EPS, TTM
- $2.07
- Gekko Fair Value
- $125.49
Trading
- Volume
- 472,147
- Avg volume, 20 days
- 590,430
- 52-week high
- $110.45
- 52-week low
- $47.32
- Shares outstanding
- 45.50M
Financials
- Revenue, TTM
- $1.35B
- Profit margin
- 7.1%
- Return on equity
- 11.2%
- Quarterly earnings growth, YoY
- +2.9%
Risk and income
- Beta
- 0.54
- Typical daily move
- ±2.5%
- Typical 20-day move
- ±6.8%
Haemonetics stock news this week
3 headlines about Haemonetics from the past week, newest first, each linking to the publisher.
- Haemonetics (HAE) is a Top-Ranked Momentum Stock: Should You Buy?Zacks Investment Research, Sep 24
- Haemonetics Corporation (HAE) Stock Price, News, Quote & HistoryYahoo! Finance Canada, Sep 23
- HAE - Haemonetics Corp Volatility & GreeksFinviz, Sep 21
Haemonetics peers
Haemonetics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Distribution | 23.7% above |
| ABTAbbott Laboratories | Accumulation | 15.0% below |
| DHRDanaher | Distribution | 10.2% above |
| ISRGIntuitive Surgical | Neutral | 17.0% above |
| MDTMedtronic | Accumulation | 24.1% below |
| SYKStryker | Accumulation | 14.1% below |
A peer links to its own page where one exists.
Haemonetics stock FAQ
What is Haemonetics’s market cap?
Haemonetics’s market cap is $4.81B at the Sep 28, 2026 close of $105.79, with 45.50M shares outstanding. The shares trade on a P/E ratio of 50.9.
What is the Haemonetics stock forecast?
The consensus analyst 12-month price target for Haemonetics is $111.50, +5.4% from the last close. Of the 8 firms that rated the stock in the last 90 days, 6 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Haemonetics stock overvalued or undervalued?
On Gekko’s estimate Haemonetics is undervalued: the Sep 28, 2026 close of $105.79 is 15.7% below Gekko Fair Value of $125.49. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Haemonetics report earnings next?
Haemonetics is expected to report on Nov 5, 2026, before the market opens (37 days away). Analysts expect earnings of $1.30 per share on revenue of $345.1M. Haemonetics beat the earnings estimate in 8 of its last 8 reports, moving 14.7% on average across the report.
What is Haemonetics’s 52-week high and low?
Haemonetics’s 52-week high is $110.45 and its 52-week low is $47.32; it closed at $105.79 on Sep 28, 2026, +121.9% over the past year.
Is Haemonetics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, fair value and earnings risk), 2 as mixed (gekkoindex and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Haemonetics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.